The market for chronic osteoarticular diseases continues to expand, and there is a robust clinical demand for anti-inflammatory and analgesic products. Nabumetone, as a non-acidic precursor drug of non-steroidal anti-inflammatory drugs (NSAIDs), has become a clinically preferred choice for rheumatic pain, osteoarticular diseases, and soft tissue inflammation due to its gastrointestinal safety advantage.

This product is naphthalene butyl ketone raw material, produced by a large-scale manufacturer in compliance with regulations, with a complete DMF file, meeting ICH pharmacopoeia standards, and benchmarked against the quality of multiple national drug regulatory systems.

The clinical core advantage of nabumetone lies in its ability to be converted into active metabolites after oral administration, exerting its effect with minimal direct irritation to the gastric mucosa. Compared to traditional non-steroidal anti-inflammatory drugs, it has a lower incidence of gastrointestinal adverse reactions. Clinically, nabumetone is used for rheumatoid arthritis, osteoarthritis, periarthritis of shoulder, soft tissue injury, and mild to moderate postoperative pain. It is well-received by middle-aged and elderly patients with osteoarthritis, and has a solid sales foundation in primary hospitals, chain pharmacies, and clinics.

Quality compliance: The complete set of technical documents is available, with DMF filing, complying with domestic and international pharmacopoeias, and supporting port inspection, domestic and international registration and application

Process stability: controlled impurity levels, stable crystal form, suitable for the production of tablets and capsule formulations

Market rigid demand: rheumatoid arthritis and osteoarthritis market, with a wide audience, strong repurchase intention, and high recognition among doctors and patients

Supply chain guarantee: sufficient production capacity, stable supply, controllable delivery time, and avoidance of supply interruption risks

Diversified cooperation model: bulk supply of active pharmaceutical ingredients (APIs), capable of cooperating with customers in joint application for preparations and OEM cooperation

In the era of centralized procurement, product selection takes into account clinical value, regulatory compliance, and a stable supply chain. We now invite cooperation from domestic and international pharmaceutical companies and traders, providing complete registration technical information to jointly explore the blue ocean market of pain management.